Alumis Inc. reported third quarter 2026 financial results and confirmed it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company ended the quarter with $344.4 million in cash and cash equivalents, which is expected to fund operations into 2027.
Term
Q3 2026
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”
Martin Babler, President and Chief Executive Officer of Alumis
Cibus, Inc. reported financial results for the third quarter of 2026, highlighting progress in its rice herbicide-tolerance traits and the initiation of manufacturing for its first two biofragrance products. The company reduced its year-to-date cash usage by 19% year-over-year and expects to exit 2026 with an annualized net cash usage run rate of approximately $35 million.
Term
Q3 2026
“Three months ago I described three ways our platform creates value: platform programs that generate revenue today, royalties as our traits reach acres, and partnerships that deepen over time. Each of these moved closer this quarter. We received requests from our customer for larger quantities of two biofragrance products to advance their product development. Our Rice traits performed well in Latin American field trials and are now being tested where it counts, in our customer Interoc's own varieties in its own fields. Further, a second partner-funded crop program, Mustard in India, began work in the quarter.”
Candel Therapeutics reported a significant increase in cash and cash equivalents to $203.1 million as of September 30, 2026, primarily driven by $142.6 million in net proceeds from public and at-the-market equity offerings. However, the company experienced a substantial increase in net loss to $69.6 million for the first nine months of 2026, compared to $8.7 million in the prior year, largely due to higher R&D spending and a negative swing in the fair value of warrant liabilities.
LifeMD reported Q3 2026 revenue of $44.6 million and a GAAP net loss of $5.2 million, while improving adjusted EBITDA sequentially by $3.1 million. The company also announced it secured a $12.5 million senior secured term loan from Avenue Venture Opportunities Fund II and Avenue Growth Lending Fund to replace its previous credit facility.
Term
Q3 2026
“We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending $9.5 million less on marketing. We’re helping more people access high-quality healthcare, and we’re getting more efficient at doing it. From May to September, cost per acquisition fell 32% while monthly media spend declined 45%. Adjusted EBITDA improved approximately $3.1 million sequentially to roughly breakeven, and we expect to sustain or improve these unit economics going forward.”
Justin Schreiber, Chairman and CEO of LifeMD
“Revenue of $44.6 million was below our guidance, and we are resetting our outlook for the fourth quarter and full year. We deliberately reduced marketing spend and prioritized longer patient commitments, and our partnerships took longer to ramp than we expected. Those factors weighed on revenue this quarter, but we believe our decisions put us in a stronger position to grow profitably.”
PEDEVCO CORP reported a 1-for-20 reverse stock split effective March 13, 2026, which has been retroactively applied to all share data. As of November 9, 2026, the company had 13,282,934 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
Ascend Wellness Holdings reported Q3 2026 net revenue of $130.0 million, a 4.2% year-over-year increase, driven by record retail transaction volumes. The company generated $31.1 million in Adjusted EBITDA and ended the quarter with 56 retail stores, subsequently expanding to 61 locations. Management highlighted strong operating leverage and positive cash flow from operations despite a significant semi-annual interest payment.
Term
Q3 2026
“Our third quarter results demonstrate the strength of our retail platform and the growing demand for our brands. We achieved record transaction volume and expanded our footprint ahead of schedule, positioning Ascend for continued growth as we optimize our operations and prepare for potential regulatory shifts in the industry.”
Hour Loop, Inc. reported net income of $2.30 million for the nine months ended September 30, 2026, on revenues of $95.95 million, representing an 11% revenue increase year-over-year. Despite higher sales, net income slightly decreased from $2.36 million in the prior year period due to increased cost of revenues and selling expenses.
Relmada Therapeutics reported third quarter 2026 financial results and provided a corporate update on its NDV-01 and sepranolone programs. The company ended the quarter with $202.1 million in cash, which is expected to fund operations through 2029, and remains on track to submit an IND for NDV-01 by year-end 2026.
“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program.”
Sergio Traversa, Chief Executive Officer of Relmada Therapeutics
“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability. Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”
Bipin Dalmia, Chief Business Officer of Relmada Therapeutics
OptimumBank Holdings reported Q3 2026 net income of $7.2 million, or $0.30 per diluted share, representing a 67% increase in EPS compared to the prior year. The company saw strong balance sheet growth with the gross loan portfolio increasing 12.3% sequentially to $1.37 billion and total deposits rising 10.6% to $1.34 billion.
Fluent, Inc. reported Q3 2026 revenue of $53.6 million, a 14% increase year-over-year, driven by a 100% growth in its Commerce Media Solutions segment. The company significantly reduced its net loss to $3.1 million from $7.6 million in the prior year and achieved breakeven Adjusted EBITDA.
Term
Q3 2026
“The third quarter was another strong quarter for us, driven by the continued growth of Commerce Media Solutions, which now represents 70% of our revenue and is operating at an annual revenue run rate that exceeds $145 million. Revenue from our aggregate continuing businesses grew 29% year-over-year in the third quarter, an acceleration from 25% in the second quarter. Commerce Media Solutions continues to reshape the profile of our Company. It is driving our growth, improving the quality of our revenue, and was a key contributor to delivering near-breakeven adjusted EBITDA this quarter.”
Don Patrick, Chief Executive Officer
“We continue to add new partners to our network, and we’re highly encouraged by the demand we’re seeing for our commerce media offerings across the markets we serve. As our revenue mix improves and our margin profile strengthens, we believe we are well positioned to close out a strong year. We remain confident in delivering full-year double-digit revenue growth on our aggregate continuing businesses with improved full-year adjusted EBITDA.”
GrabAGun Digital Holdings reported Q3 2026 net revenues of $21.2 million, a 4.7% decrease year-over-year due to lower product sales. Despite the revenue dip, gross profit increased 44% and gross margin expanded 480 basis points to 14.4%, driven by improved sourcing and disciplined purchasing.
Term
Q3 2026
“Our third-quarter results reflect the progress we are making in improving the quality and profitability of our business. Gross profit increased 44% and gross margin expanded 480 basis points to 14.4%, primarily driven by average selling prices and supported by better sourcing, a stronger product cost basis and disciplined purchasing.”
Marc Nemati, Chairman and Chief Executive Officer
“Subsequent to quarter end, we completed the acquisition of Camfour, a New England-based wholesale distributor funded entirely with cash on hand and without financing or issuing shares. We believe combining Camfour's distribution capabilities with our e-commerce and logistics platform will stimulate growth, expand our customer base and improve our purchasing economics.”
United States Antimony Corp reported Q3 2026 revenue of $10.1 million, a 16% increase year-over-year, driven by a 68% surge in antimony pounds sold. Despite a 113% increase in gross profit to $4.3 million, the company reported a net loss of $9.5 million, impacted by non-cash stock-based compensation and an unrealized loss on its Larvotto Resources investment.
Equillium reported third quarter 2026 financial results, highlighting the initiation of a Phase 1 clinical trial for EQ504 with proof-of-mechanism data expected in Q2 2027. The company strengthened its balance sheet with a $20 million financing tranche closed in October 2026, extending its cash runway into 2029.
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program. We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.”
Bruce Steel, Chief Executive Officer of Equillium
“We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”
Sanara MedTech reported Q3 2026 net revenue of $28.4 million, an 8% increase year-over-year, and Adjusted EBITDA of $5.6 million. The company recorded a net loss from continuing operations of $1.3 million, which included $3.0 million in legal and advisory costs related to its pending merger with MiMedx Group, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics, with its lead candidate PLN-101095 currently in Phase 1a/1b trials. The company reports significant net losses since inception and expects to require substantial additional capital to fund its ongoing research and development activities.
Rhinebeck Bancorp, Inc. reported net income of $3.15 million for the quarter ended September 30, 2026, compared to $2.70 million in the prior year period. The company completed its conversion to a fully public company on July 21, 2026, resulting in a significant increase in total stockholders' equity to $220.8 million.
Socket Mobile reported a 9% increase in Q3 2026 revenue to $3.39 million, though year-to-date revenue remains down 8.9% compared to 2025. The company continues to operate at a loss, reporting a net loss of $0.79 million for the quarter and $3.04 million for the first nine months of 2026, as it manages high operating expenses relative to gross profit.
Eledon Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $69.7 million and progress in its tegoprubart clinical program. The company remains on track to initiate its global Phase 3 LEGACY trial in kidney transplantation in Q4 2026 and recently received FDA Fast Track designation for the candidate.
Term
Q3 2026
“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end.”
David-Alexandre C. Gros, M.D., Chief Executive Officer
For the 13 weeks ended October 3, 2026, Fossil Group reported net sales of $271.2 million and net income attributable to the company of $11.7 million, a significant recovery from the $39.9 million loss in the prior year period. For the 39-week period, the company achieved a narrow net income of $0.2 million compared to a $59.7 million loss in 2025, driven by improved gross margins and reduced operating expenses.
Shimmick Corporation reported a net income of $0.8 million for the third quarter of 2026, a significant improvement from a $4.4 million loss in the prior year period, despite a slight decrease in revenue to $135.8 million. For the nine months ended October 2, 2026, the company reduced its net loss to $8.4 million compared to $22.5 million in 2025, driven by improved gross margins and equity in earnings from joint ventures.
Arcadia Biosciences reported third-quarter 2026 financial results, highlighted by a 24% year-over-year increase in total revenues to $1.6 million. The growth was primarily driven by record quarterly sales for the Zola coconut water brand, which benefited from strong summer promotional programs and expanded distribution.
Term
Q3 2026
“The third quarter was very strong for Zola® with revenues growing 24% compared to the same quarter last year, resulting in the highest quarterly sales the brand has ever reported.”
T.J. Schaefer, CEO of Arcadia
“We are extremely excited to begin shipping our newly formulated espresso flavor this month after receiving pre-launch commitments from several of our leading customers.”
Binah Capital Group reported a significant increase in net income to $4.89 million for the nine months ended September 30, 2026, compared to $2.14 million in the prior year period. Total revenues grew to $145.8 million, driven primarily by higher commission and advisory fee income, while the company maintained a strong cash position of $13.2 million.
Middleby Corp reported net sales of $1.90 billion for the first nine months of 2026, up from $1.75 billion in the prior year, though net earnings were significantly impacted by a $129.1 million loss from discontinued operations. The company completed the Midera spin-off during the period, resulting in a $780.2 million reduction in stockholders' equity.
Sunshine Silver Mining & Refining Company completed its IPO in June 2026, raising $291.9 million in net proceeds, significantly strengthening its cash position to $261.4 million. The company reported a net loss of $50.9 million for the nine months ended September 30, 2026, driven primarily by increased pre-development and general administrative expenses as it scales operations.
TriplePoint Private Venture Credit Inc. reported a significant turnaround for the nine months ended September 30, 2026, with a net increase in net assets resulting from operations of $39.5 million compared to a $3.0 million loss in the prior year period. This improvement was primarily driven by $34.2 million in net change in unrealized gains on investments, despite a slight decrease in total investment income.
Northpointe Bancshares Inc. is an emerging growth company that operates as a non-accelerated filer. The filing highlights risks related to the mortgage banking sector, including the proposed sale of its distributed retail and consumer direct mortgage origination channels and the impact of prolonged elevated interest rates on loan demand and liquidity.
Virgin Galactic reported a net loss of $58.8 million for the third quarter of 2026, an improvement from the $64.4 million loss in the prior year period. The company is focused on developing its next-generation Delta Class vehicles while managing a significant reduction in research and development expenses as it transitions through its flight fleet development phases.
Andersen Group Inc. reported total assets of $758.7 million as of September 30, 2026, a significant increase from $565.1 million at year-end 2025, driven largely by higher accounts receivable and the recognition of deferred tax assets. The company maintains a dual-class stock structure and reported an accumulated deficit of $790.5 million, reflecting ongoing investments in scaling its AI-driven service offerings and business expansion.
Brookfield Private Equity Fund LP is a non-accelerated filer and emerging growth company that reported various unit classes outstanding as of October 31, 2026, including 24.6 million Class B-1 units. Effective September 1, 2026, the fund ceased offering Class D units, focusing its non-Brookfield investor offerings on Class I and Class S units.
Accelevation Holdings Corp. reported its first quarterly results as a public company, with revenue growing 66% year-over-year to $202.2 million. The company saw significant demand with bookings of $768.9 million and a backlog reaching $1.7 billion, driven by mission-critical infrastructure needs.
Term
Q3 2026
“At Accelevation, we design, manufacture, and install mission-critical infrastructure for customers who rely on our speed and certainty of delivery, and our third quarter results reflect the strength of our operating model and underlying markets.”
Michael Rubiera, Co-Founder and Chief Executive Officer
“We delivered strong growth, profitability, and cash generation in the quarter. Revenue increased more than 60%, bookings grew more than 350%, backlog rose to approximately $1.7 billion, and Adjusted EBITDA margins approached 19% following a weaker first half.”